Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$119.08

0.27 (0.23%)

06:35
02/14/19
02/14
06:35
02/14/19
06:35

Eli Lilly, Boehringer Ingelheim announce CAROLINA trial meets primary endpoint

Boehringer Ingelheim and Eli Lilly announced CAROLINA met its primary endpoint, defined as non-inferiority for Tradjenta versus glimepiride in time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. CAROLINA is the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4, or DPP-4, inhibitor. The trial evaluated the cardiovascular safety of Tradjenta compared with the sulfonylurea glimepiride, on top of standard of care, in 6,033 adults with type 2 diabetes and increased cardiovascular risk or established cardiovascular disease. The study assessed Tradjenta safety over the longest period ever studied in a DPP-4 inhibitor cardiovascular outcome trial, with a median follow-up of more than 6 years. The overall safety profile of Tradjenta in CAROLINA was consistent with previous data, and no new safety signals were observed. People with type 2 diabetes have an increased risk of cardiovascular disease, and despite recent advancements in treatment options, cardiovascular disease remains the leading cause of death for this population. Together with CARMELINA, which demonstrated similar long-term cardiovascular safety compared with placebo in adults with type 2 diabetes at high risk for cardiovascular and/or kidney disease, CAROLINA confirms the long-term overall safety profile of Tradjenta in a broad range of adults with type 2 diabetes.

  • 14

    Feb

  • 18

    May

LLY Eli Lilly
$119.08

0.27 (0.23%)

01/18/19
WBLR
01/18/19
DOWNGRADE
WBLR
Market Perform
Loxo Oncology downgraded to Market Perform from Outperform at William Blair
William Blair analyst Raju Prasad downgraded Loxo Oncology (LOXO) to Market Perform citing the likelihood of the takeover by Eli Lilly (LLY) closing at the agreed upon price.
01/18/19
JPMS
01/18/19
NO CHANGE
JPMS
Overweight
Eli Lilly trial miss a 'moderate setback,' says JPMorgan
JPMorgan analyst Chris Schott calls Eli Lilly's Phase 3 trial miss of Lartruvo in combination with doxorubicin in patients with advanced or metastatic soft tissue sarcoma a "moderate" setback.
01/23/19
UBSW
01/23/19
INITIATION
Target $131
UBSW
Buy
Eli Lilly initiated with a Buy at UBS
UBS analyst Navin Jacob started Eli Lilly with a Buy rating and $131 price target. The analyst's analysis suggests the company's diabetes franchise growth, Verzenio adjuvant trial success and operating margin expansion are not fully appreciated in the stock or estimates
01/25/19
PIPR
01/25/19
NO CHANGE
PIPR
Report that CVS excluded Amgen's Aimovig 'greatly exaggerated,' says Piper
Piper Jaffray analyst Christopher Raymond kept an Overweight rating and $220 price target on Amgen (AMGN) following a Reuters report from earlier on Friday which stated that CVS (CVS) has excluded Amgen's Aimovig from its formulary. The analyst called the report "Friday afternoon clickbait" and noted that while CVS currently provides preferred status to Teva's (TEVA) Ajovy and Eli Lilly's (LLY) Emgality, this was made public in late 2018. In a check with management, Raymond found out the decision only encompasses about one-third of CVS network, that CVS is actively working to improve this access, and that 70% of commercial migraine patients have contracted access to Aimovig. Raymond concluded that this was "not something to worry about" in his view, and did not change his Q4, FY19, or FY20 estimates on Aimovig. In Friday trading, shares of Amgen were down just over 1% to $198.77.

TODAY'S FREE FLY STORIES

DBVT

DBV Technologies

$7.70

-0.26 (-3.27%)

12:05
02/22/19
02/22
12:05
02/22/19
12:05
Periodicals
JAMA editorial says DBV trial results 'not easy to interpret' »

In an editorial published…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GME

GameStop

$11.15

0.12 (1.09%)

12:05
02/22/19
02/22
12:05
02/22/19
12:05
Options
GameStop call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LTN

Union Acquisition Corp

$5.89

-1.44 (-19.65%)

12:00
02/22/19
02/22
12:00
02/22/19
12:00
Hot Stocks
Union Acquisition Corp falls -17.3% »

Union Acquisition Corp is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

TDS

Telephone and Data

$32.14

-4.55 (-12.40%)

12:00
02/22/19
02/22
12:00
02/22/19
12:00
Hot Stocks
Telephone and Data falls -12.5% »

Telephone and Data is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

DPLO

Diplomat Pharmacy

$7.65

-5.81 (-43.16%)

12:00
02/22/19
02/22
12:00
02/22/19
12:00
Hot Stocks
Diplomat Pharmacy falls -42.9% »

Diplomat Pharmacy is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 11

    Mar

  • 12

    Mar

PBI

Pitney Bowes

$8.25

1.225 (17.45%)

12:00
02/22/19
02/22
12:00
02/22/19
12:00
Hot Stocks
Pitney Bowes rises 17.4% »

Pitney Bowes is up 17.4%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 28

    Mar

SWM

Schweitzer-Mauduit

$41.20

6.51 (18.77%)

12:00
02/22/19
02/22
12:00
02/22/19
12:00
Hot Stocks
Schweitzer-Mauduit rises 19.0% »

Schweitzer-Mauduit is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 28

    Mar

W

Wayfair

$153.23

36.09 (30.81%)

12:00
02/22/19
02/22
12:00
02/22/19
12:00
Hot Stocks
Wayfair rises 30.9% »

Wayfair is up 30.9%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 03

    Mar

CAG

Conagra Brands

$23.13

-0.95 (-3.95%)

11:55
02/22/19
02/22
11:55
02/22/19
11:55
Options
ConAgra put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:55
02/22/19
02/22
11:55
02/22/19
11:55
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

11:55
02/22/19
02/22
11:55
02/22/19
11:55
Conference/Events
William Blair medical tech analyst to hold a luncheon »

Medical Technology &…

TKR

Timken

$43.82

0.41 (0.94%)

11:51
02/22/19
02/22
11:51
02/22/19
11:51
Conference/Events
Timken management to meet with KeyBanc »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

KPTI

Karyopharm

$8.97

0.01 (0.11%)

11:50
02/22/19
02/22
11:50
02/22/19
11:50
Recommendations
Karyopharm analyst commentary  »

H.C. Wainwright sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 06

    Apr

JEC

Jacobs Engineering

$74.22

0.45 (0.61%)

11:48
02/22/19
02/22
11:48
02/22/19
11:48
Conference/Events
Jacobs Engineering management to meet with KeyBanc »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 12

    Mar

TCDA

Tricida

$23.11

0.84 (3.77%)

11:46
02/22/19
02/22
11:46
02/22/19
11:46
Initiation
Tricida initiated  »

Tricida initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPS

UPS

$109.87

-1.89 (-1.69%)

11:45
02/22/19
02/22
11:45
02/22/19
11:45
Options
UPS call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

11:45
02/22/19
02/22
11:45
02/22/19
11:45
General news
More from Williams: the Phillips Curve needs to be taken seriously »

More from Williams: the…

OCUL

Ocular Therapeutix

$4.22

0.61 (16.90%)

11:37
02/22/19
02/22
11:37
02/22/19
11:37
Hot Stocks
Ocular Therapeutix higher after pricing $37.5M in convertible notes »

Shares of Ocular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:35
02/22/19
02/22
11:35
02/22/19
11:35
General news
The Fed's Monetary Policy Report »

The Fed's Monetary…

AXNX

Axonics

$21.65

-0.85 (-3.78%)

11:33
02/22/19
02/22
11:33
02/22/19
11:33
Hot Stocks
Axonics granted expanded CE mark label approval for Axonics r-SNM System »

Axonics Modulation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

  • 05

    Mar

EA

Electronic Arts

$95.01

-1.825 (-1.88%)

11:30
02/22/19
02/22
11:30
02/22/19
11:30
Options
Buyer pays $3.3M for EA upside calls as shares drop 2% »

Buyer pays $3.3M for EA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

VLKAY

Volkswagen

$0.00

(0.00%)

11:27
02/22/19
02/22
11:27
02/22/19
11:27
Periodicals
VW CEO says he hopes company did enough 'to avoid import taxes', CNBC reports »

Volkswagen CEO Herbert…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$19.10

1.68 (9.64%)

11:25
02/22/19
02/22
11:25
02/22/19
11:25
Options
Amarin call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

MDT

Medtronic

$93.25

0.65 (0.70%)

11:25
02/22/19
02/22
11:25
02/22/19
11:25
Conference/Events
Medtronic participates in a conference call with JPMorgan »

Healthcare Analyst Marcus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 25

    Feb

  • 06

    Mar

  • 18

    May

  • 28

    May

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
02/22/19
02/22
11:17
02/22/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.